Ipsen to buy cancer drugs from Merrimack
French drugmaker Ipsen has entered into a definitive agreement to buy the global oncology assets from the USA’s Merrimack Pharmaceuticals, in a deal that could be worth around $1 billion.
Read More
Tag: Merrimack
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
